QQ客服 官方微博 反馈留言

	Plasma miR-142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy
	Tang, Qian-jie; Lei, He-ping; Wu, Hong; Chen, Ji-yan; Deng, Chun-yu; Sheng, Wang-sheng; Fu, Yong-heng; Li, Xiao-hong; Lin, Yu-bi; Han, Ya-ling
刊名	ACTA PHARMACOLOGICA SINICA
	2019
卷号	Vol.40 No.2页码:208-215
关键词	plasma miRNAs miR-142 antiplatelet therapy MACEs coronary artery disease
ISSN号	1671-4083
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4745128
专题	湖南大学
作者单位	1.Guangdong Acad Med Sci, Guangdong Gen Hosp, Guangdong Cardiovasc Inst, Guangdong Prov Key Lab Coronary Heart Dis Prevent, Guangzhou, Guangdong, Peoples R China 2.South China Univ Technol, Med Sch, Guangzhou, Guangdong, Peoples R China 3.Guangdong Women & Children Hosp, Dept Pharm, Guangzhou, Guangdong, Peoples R China 4.Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou, Guangdong, Peoples R China 5.Shenyang Northern Hosp, Cardiovasc Res Inst, Shenyang, Liaoning, Peoples R China 6.Shenyang Northern Hosp, Dept Cardiol, Shenyang, Liaoning, Peoples R China
推荐引用方式 GB/T 7714	Tang, Qian-jie,Lei, He-ping,Wu, Hong,et al. Plasma miR-142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy[J]. ACTA PHARMACOLOGICA SINICA,2019,Vol.40 No.2:208-215.
APA	Tang, Qian-jie.,Lei, He-ping.,Wu, Hong.,Chen, Ji-yan.,Deng, Chun-yu.,...&Han, Ya-ling.(2019).Plasma miR-142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy.ACTA PHARMACOLOGICA SINICA,Vol.40 No.2,208-215.
MLA	Tang, Qian-jie,et al."Plasma miR-142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy".ACTA PHARMACOLOGICA SINICA Vol.40 No.2(2019):208-215.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。